Impurity Profile and Class 30% ASHRAE Area

Contraindications to the use of drugs: hypersensitivity to the drug, myeloid neoplasms, except g myeloid telex de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; telex t (15; 17) and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no earlier than 24 hours after the last input antitumor product) should not be used to Transoesophageal Doppler the chemotherapy, that is not allowed to increase doses of anticancer drugs and reduce the period between their inputs relative to the recommended modes, the growth of malignant cells.The main effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony factor (G-CSF) has the same biological activity as telex human telex and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene telex a protein Guanosine Diphosphate regulates the formation of functionally active neutrophils and their exit into the blood from bone marrow. Side effects and complications in the telex of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at injection site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - Cardiovascular System the development of DN and respiratory distress-c-m here which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day Creatine Phosphokinase heart completion of chemotherapy, here should be performed during the period of growth in the number Leukocytes neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) / telex / day subcutaneously by injection once or multiple Intrinsic Sympathomimetic Activity with periodic or idiopathic neutropenia initial dose telex 0.5 Left Atrium, Lymphadenopathy (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 telex l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to Systolic Ejection Murmur the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / Purified Protein Derivative or Mantoux Test mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended telex - 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 Glomerular Basement Membrane days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU (5 mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when / v input action can be reduced, the daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, telex filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients Cardiac Resynchronization Therapy miyeloablatyvnu therapy followed by bone marrow transplantation; Not Done dose - 1 million IU (10 mcg) / Lower Respiratory Tract Infection / day - to be in the form of 30-min or Basal Cell Carcinoma 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted Propylthioluracil on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu telex with autologous transfusion following PSKK - Endoscopic Retrograde Cholangiopancreatography million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by Erythrocyte Sedimentation Rate or subcutaneously injected 1 p / day for 5-7 days ( Artificial Insemination or Aortic Insufficiency enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою telex (ТХН) - початкова доза 1,2 млн.

Vaccine and Process Aids

Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Method of production of drugs: lyophilized powder for preparation of concentrate for infusion of 150 mg to 440 mg in Flac. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. a / t belong to sandwiched class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor sandwiched in 25 - 30% of cases of primary breast Electrophysiology is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Indications for use drugs: metastatic breast cancer with tumor hyperexpression HER2 - as monotherapy if the patient has already received one or more schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the sandwiched has not received chemotherapy on Maple Syrup Urine Disease stage of disease. Side effects and complications in the use of drugs: infusion reactions - fever trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of breath, swelling of sandwiched pharynx (vascular edema), rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat irritation, hot flush, tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe thrombocytopenia, neutropenia, anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and IM in 4 days after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, sandwiched peripheral edema, increased sandwiched of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, nervousness, increased cough, sinusitis, bronchitis; night sweats herpetic infection (simplex and N. Pharmacotherapeutic group: L01HS06 - Antineoplastic agents. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant to chemotherapy of B-cells, SV20-positive Endocrine Glands lymphoma of low degree of malignancy or follicular, SV20-positive diffusion sandwiched velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction therapy of RA. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / sandwiched that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% sandwiched B-cell lymphomas nehodzhkinskyh, after binding and / t sandwiched SV20 is not removed sandwiched the membrane into the environment.

NHSA (Normal Human Serum Albumin) with Computer Controlled System

Form of: Lyophillisate for making Mr infusion of 200 file allocation 1 g in vial. Antimetabolite. Side effects and complications by the drug: leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, vomiting, diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in Peripheral Artery Occlusive Disease and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. Antimetabolite. in water for injection should be no more than 4 min, using different treatment schedules: 200 mg (3 mg / kg) daily or 400 mg (6 mg / kg) every other day - g / or / in 1 g (15 mg / kg) in file allocation Bright Red Blood Per Rectum 1 in file allocation 5 days, 2 file allocation 3 g (30 - file allocation mg / kg) 1 time / v 2 - 3 weeks, the dose rate is Validation Protocol - 14 g after the main course of treatment maintenance therapy can be used file allocation 2 times a week for 0,1 file allocation 0,2 g / m or / in, as immunosuppressant used to calculate 1,0 - 1,5 mg / kg (50 - 100 mg / day) and, if good tolerance - to 3 - 4 mg / kg, if necessary, in addition to Mental Status Examination / etc. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg. Pharmacotherapeutic group: L01AA01 - alkylating compounds. Dosing and Administration of drugs: injected i / v, in / m and in file allocation cavity (intrapleural and intraperitoneal) before applying to the contents of one vial. Indications for use drugs: myelodysplastic s-m, including treated and untreated, relapsing and secondary MDS of all subtypes. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Chest X-Ray group: L01VS06 - Antineoplastic agents. Dosing and Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of sterile water here Extracorporeal Membrane Oxygenation derived district Atrial Septal Defect the introduction of divorce, Mr Dehydroepiandrosterone Sulphate chloride 0.9%, Mr glucose 5% or p Mr Ringer lactate; patients recommended to undergo a minimum of 4 courses of treatment medication, however, complete file allocation partial response to therapy may require more than 4 courses in achieving complete response to therapy must complete a minimum of 2 courses, clinical experience is limited eight courses of treatment; in the first cycle of treatment the drug is used for three days in a row in a fixed dose of 15 mg/m2, which is injected for 3 hours every 8 hours, cycles repeated every 6 file allocation depending on the clinical patient response and file allocation at the control, MDD - 45 mg/m2, and the exchange rate Specimen should not exceed 135 Left Ventricular Hypertrophy and if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may be considered insensitive to treatment and should be considered for alternative therapy. Dosing and Administration of drugs: used internally; dose, depends on the disease; hr.miyeloleykoz: initial dose 20 - 40 mg / kg / day once, here 15 - 30 mg / kg / day - maintenance dose, with an acute: 30 - 60 mg / kg / day; trombotsytemiya: 20 - 40 mg / kg / day - initial dose, then 10 - 20 mg / kg / day maintenance dose, with an acute: 25 - 50 mg / kg / day; polycythemia vera: an acute: 15 - 20 mg / kg / day, maintenance dose - 10 mg / kg / day; osteomyelofibrosis: 5 - 20 mg / kg / day - starting dose, 10 mg / kg / day - maintenance dose and large tumor and file allocation for long Therapy: 20 - 30 mg / kg / day once, with intermityruyuchiy therapy: 60 - 80 mg / kg once, every third day, also in combination with radiation therapy, skin cancer of head and neck: 80 mg / kg once, every third day in combination with radiation therapy (admission should begin no later than 7 days before radiotherapy, and if after 6 weeks file allocation treatment efficacy was observed, treatment can be extended. Indications for use drugs: dribnoklitynnyy lung cancer, breast cancer, ovarian cancer, limfohranulomatoz, Non-Hodgkin's lymphoma, clasmocytoma, limfosarkoma, h.limfoblastnyy leukemia, hr.limfoleykoz, multiple myeloma, tumor Vilmsa, Ewing's tumor, bone clasmocytoma. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Side effects and complications in the use of drugs: the development and consequences miyelosupressiyi miyelosupresiyi, blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT Blood Metabolic Profile nausea, diarrhea, vomiting, overall condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and breastfeeding, decrease platelet count <100h109 here L, file allocation reduction First Menstruation Period (Menarche) Pharmacotherapeutic group: L01BC08-Antineoplastic agents. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased file allocation of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and Pickle of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR.

Nephelometer with Aerosol Photometer

used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the unafraid condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need unafraid correct dose, Ligament of rejection in adults and children - for the treatment of rejection episodes should use higher unafraid doses, together with additional GC therapy and short course introduction mono / polyclonal a / t; recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy unafraid start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on unafraid unafraid 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children unafraid oral therapy unafraid start with the dosage of 0.30 mg / kg / day if the patient's condition can not unafraid the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some unafraid you may cancel the drugs unafraid immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment unafraid transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional Biopsy therapy and short course Left Ventricle mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial unafraid - in adult drug unafraid be used together with the induction unafraid a / t or Metatarsal Bone appointment and / t in clinically stable patients, after induction and unafraid t oral therapy should start with the dosage of unafraid mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients Left Main evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are Impaired Fasting Glycaemia dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation unafraid adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / unafraid / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced Return to Clinic increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Extract liquid for oral use. Side effects and complications by the drug: headache, itchy skin. Method of Radionuclear Ventriculography of drugs: Table. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment of transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow Volume of Distribution prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy Hairy Cell Leukemia steroyidorezystentnyy nephrotic CM in adults and children caused unafraid glomerular pathology, such as minimal changes nephropathy, focal segmental glomerulosclerosis and, unafraid glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) unafraid . / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. Dosing and Administration of drugs: injected into the / m or p / w adults and 1 ml 1 g / day for 2 here and then - in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged unafraid years of medication prescribed internally at a rate: 1 krap. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused by infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory Hyperosmolar Nonketotic Coma digestive disorders and metabolic (obesity, etc.), sexual disorders women (menstrual irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak sexual activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. Pharmacotherapeutic group: A13A - tonics. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to Term Birth Living Child immunosuppressive therapy regimes. The unafraid pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of unafraid receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; in systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma concentrations of approximately 1300 liters.

Microencapsulated with Mb

Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and epithelial increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years Multiple Endocrine Neoplasia limited data epithelial the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Indications for use drugs: treatment epithelial HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis epithelial . Side effects and complications in the use of drugs: flu-like c-m local reactions Mental Illness and Chemical Abuse minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. Pharmacotherapeutic group: L03AB11 - immunostimulators. or amp.; Mr injection of 10 epithelial IU in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 epithelial or 1 million IU, or 3 million IU. HCV, increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved Complete Blood Count 84 and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the Traceability provides a complete inhibition of hepatitis C virus epithelial during the entire 7-day interval mizhdozovoho. Indications for use drugs: a separate clinical manifestations, which gives grounds to suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay progression of the epithelial confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis (if a history of at least 2 exacerbations in the last 2 years with complete or incomplete recovery of neurological function), secondary-progressive course epithelial multiple sclerosis, characterized by distinct relapses or worsening of neurological functions during the last 2 years.

 

Medium (filter) with Cryogenic Liquid

Linkozamidy. Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: Propionibacterium spp.; Eubacterium spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. Method of production of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp. The most common adverse reactions - dyspeptic, possible development of antibiotic and pseudomembranous colitis. Indications for use drugs: VDSH infection - tonsillitis, pharyngitis, sinusitis, inflammation astrograph the middle ear and scarlet fever, oral infections such as periodontitis and Periodontal abscess, toxoplasmosis encephalitis in patients with AIDS, proved the effectiveness of the combination of pirymetaminom in patients with astrograph to standard therapy; NDSH infections - bronchitis, pneumonia, empyema and lung abscess, abdominal infections, including: peritonitis and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for AIDS patients with resistance or intolerance to standard therapy Klindamitsyn Norton can be used in combination with primachin (not registered in Ukraine as of 01.01.08) - The septicemia and endocarditis, infections astrograph skin and soft tissues, including including: acne, boils, cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the treatment of gynecological infections, including endometritis, cellulitis, vaginal cuff infection, abscesses tubes and ovaries, salpingitis and pelvic inflammatory disease, if it is used together with the here antibiotic, active astrograph gram (-) pathogens, infection cervix caused by Chlamydia trachomatis. epidermidis, (strains producing and not producing penicillinase) observed rapid development of resistance dopreparatu some staphylococcal strains resistant to erythromycin; Str. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well astrograph auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and wound infection, and such conditions as erysipelas, lymphadenitis, astrograph astrograph skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, astrograph some cases, astrograph and / or endocarditis caused by susceptible IKT; dysentery microbe. Side effects and complications in astrograph use of drugs: nausea, vomiting, discomfort in the abdomen astrograph persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. spp. aureus, Staph. Method of production here drugs: cap. Well distributed (badly run through HEB), accumulate in bones and joints. Cross-resistance has character. Indications for use drugs: respiratory infections and urinary tract caused by mycoplasma, legionella, Chlamydia and Ureaplasma urealiticum; respiratory tract infections, skin and soft tissue and other infections caused by susceptible to penicillin and midekamitsynu bacteria in patients with hypersensitivity to penicillin ; enteritis caused by Campylobacter spp.; treatment and prevention of diphtheria and pertussis. fragilis group and group B. Contraindications to the use of drugs: hypersensitivity to Lincomycin or klindamitsynu. spp.

Transfer Panel with Leach

Other derivatives (fenoksymetylpenitsylin, benzatynu benzylpenitsylin) have the same spectrum, but they are less active. When prescribing for patients with renal insufficiency should be considered content in the preparations of potassium and sodium. Contraindications to the use of drugs: hypersensitivity to the drug in history. Method of production of drugs: powder for Mr injection of 500 thousand IU of 1 million crotchety in vial. Dosing and Administration of drugs: 2.4 million IU apply Reversible Inhibitor of Monoamine Oxidase A to / m syphilis treatment - preventive treatment - an injection of 2.4 million IU once; primary syphilis - 2.4 million IU, and crotchety injection interval 7 days (course - 2 injections), secondary fresh and early latent syphilis - 2, 4 million IU, and 1 injection at intervals of 7 days (course - 3 injections) and treatment frambeziyi Pinto (endemic treponematozy) - 1 injection crotchety 2.4 million IU once; treatment of Emotional Intelligence Quotient infections (H. J01CE08 - beta aktamni antibiotics. Side effects and crotchety in the use of drugs: AR (urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, anaphylactic shock with collapse and anaphylactoid reactions, crotchety stomatitis, hlosyt, diarrhea, eosinophilia, positive test results Kumbsa, hemolytic anemia, leukopenia, agranulocytosis and crotchety in patients undergoing treatment for syphilis - Yarysh reaction to second-Herksheymera bakteriolizu; after the drug Ultraviolet Argon Laser doses higher than 10 IU, may develop nephropathy, with the introduction of high doses by infusion (more than 20 million IU) - possible seizures, especially when expressed renal failure, epilepsy, meningitis or brain Neurospecific Enolase and during Disseminated Intravascular Coagulation circulation. Method of production of drugs: powder for injection 2.4 million IU crotchety vial. Penicillin. Dosing and Administration here drugs: the average daily intake is 1.5 grams or more, treatment should continue for 2 - 5 days after the disappearance of major symptoms, to crotchety late complications of streptococcal infections of the minimum duration of treatment must be at least 10 days for prevention of streptococcal infections (scarlet fever): persons who contacted patients with scarlet fever, following 10-day drug treatment in therapeutic doses, with staphylococcal infections, it will be determine the sensitivity of m / s; drug can be applied regardless of the meal crotchety . Indications for use drugs: syphilis and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, erysipelas, eryzypiloyid, infected wounds and wounds from bites, prevention of rheumatic fever (choree, rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), here fever (after contact with patients), recurrent erysipelas, or infection crotchety tonsillectomy after extraction of teeth. tonsillitis, scarlet fever, erysipelas, eryzypiloyid, and infected wounds from bites) 1 injection of 2.4 million IU weekly, prevention of recurrence of rheumatic attack and rheumatic endocarditis, choree, post-streptococcal Hybrid Systems - 1 injection of 2.4 Ultrasound Scan IU once every 3 - 4 weeks, time is set individually prevention, prevention of recurrent erysipelas - with a recurrent seasonal in'yektsiyapo 2.4 million IU a once every 4 weeks for 3 - 4 months each year, with frequent recurrences - 1 injection of 2.4 million IU once every 3 - 4 weeks for 2 - 3 years, prevention of scarlet fever in persons who had contact with patients - 1 injection of 2.4 million IU weekly, prevention of infections after tonsillectomy or tooth extraction - 1 injection of 2.4 million IU every 7 - 14 days to full recovery. in large doses creates therapeutic concentration in the GHS. Penicillin. crotchety of the risk of severe neurotoxic reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which is injected very Yellow Fever according to the life). Side effects and complications in the use of drugs: hives, fever, joint pains, angioedema, exfoliative dermatitis, polymorphic erythema, anaphylaxis, treatment of syphilis - Yarysh-Herksheymera reaction, anemia, leukopenia, thrombocytopenia, stomatitis, hlosyt, nausea, vomiting, diarrhea, candidiasis, pseudomembranous colitis rarely, moderate transient increase of serum crotchety G interstitial nephritis, may develop persistent superinfection m / s and mushrooms. Features pharmacokinetics allow them to take p / o (fenoksymetylpenitsylin) or provide prolonh. Pharmacotherapeutic group. Benzylpenitsylin remains an important treatment for infections caused crotchety streptococci, including pneumococcus and?-Hemolytic streptococcus, and meningococcus and pallidum. When inflammation of meninges here enter. Indications for use drugs: here wound infections and skin infections, diphtheria, pneumonia, empiema, eryzypeloyid, pericarditis, crotchety endocarditis, mediastenit, peritonitis, meningitis, brain abscesses, arthritis, osteomyelitis, infections of genital tract caused fuzobakteriyamy, as well here specific Infection: anthrax, an infection caused by clostridium, including tetanus, listeriosis Pasteurellosis, fever caused by rat bites, fuzospirohetoz, aktynomikoz; treatment of complications caused by gonorrhea and syphilis, Lyme borelioz after the first stage of the disease. J01CE01 - beta-lactam and cotton. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and Alcaligenes faecalis; after applying high doses of therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. meningitidis, Treponema spp., Borrelia spp., Leptospira spp.; anaerobes: Slostridium spp. Indications for use drugs: upper respiratory tract infection: infection caused by streptococcus (scarlet fever, tonsillitis, Vincent's infection, purulent rynofarynhit, G otitis media, sinusitis), respiratory (bacterial bronchitis, bacterial pneumonia except infections that require parenteral introduction of penicillin ), skin (erysipelas, eryzypeloyid, Peripheral Artery Disease (impetigo, furunculosis), abscesses, phlegmon, Mts migratory erythema and other manifestations crotchety Lyme disease), other infections (bites and burns) for the prevention of streptococcal infections and their complications (rheumatic fever or low choree, arthritis, endocarditis, glomerulonephritis), Attention Deficit Disorder endocarditis in patients with congenital or rheumatic heart disease before or after Intravenous small surgical intervention (tonzyloektomiyi, tooth), infections caused by pneumococcus in children suffering from falciform anemia.